News | Robotic Systems | April 24, 2017

Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System

Study of 184 patients compared latest-generation remote magnetic navigation system to previous generation in terms of procedure and fluoroscopy times for atrial fibrillation ablation procedures

Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System

April 24, 2017 — A recent study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France validated the advantages of the Niobe ES magnetic navigation system over the Niobe II system in terms of procedure and fluoroscopy times for atrial fibrillation (AF) ablation procedures. The study was published in the International Journal of Cardiology and represents the first comparison study of Stereotaxis’ latest-generation remote magnetic navigation system to its predecessor.

“Our aim with this study was to quantify the clinical improvements that we have experienced with complex arrhythmia ablations, specifically AF, since upgrading to the Niobe ES system,” said Antoine Da Costa, M.D., Ph.D., chief of the EP (electrophysiology) Unit at CHU of Saint-Étienne. “We sought to evaluate procedure duration, as well as efficacy and extent of fluoroscopic exposure associated with the Niobe ES system compared to the Niobe II in patients requiring AF ablation. Our results confirmed that the Niobe ES system reduced procedure time and X-ray exposure by a minimum of 30 percent, primarily due to the system’s enhanced responsiveness.” 

In the Saint-Étienne study, researchers compared data on 92 consecutive patients treated with the Niobe ES system to 92 consecutive patients treated using the Niobe II system for symptomatic drug-refractory atrial fibrillation. The percentage of circumferential pulmonary vein isolation, as confirmed via spiral catheter recording during ablation, was 100 percent. Procedure time was significantly lower with the Niobe ES system than the Niobe II system (1.9 ± 0.4 vs. 2.7 ± 1h, p < 0.0001), as was X-ray duration (12 ± 4 vs. 15 ± 7 min, p = 0.001).

The EP Unit at CHU of Saint-Étienne first implemented Stereotaxis technology in 2009 and installed a second Niobe system in 2015. They are recognized as a national center of excellence, consistently ranked in the top five for interventional cardiology in France, as well as a European center of reference in the treatment of complex arrhythmias. 

The Niobe ES system constitutes Stereotaxis’ fourth-generation magnetic navigation technology, designed to improve functionality through faster computing hardware, new motion controllers and a more intuitive user interface. By creating a near real-time response to catheter movement commands, the Niobe ES enables an operator to navigate an ablation catheter more quickly, precisely and with little fluoroscopic guidance. The ensuing results can be faster anatomy-specific ablation procedures with significantly less X-ray exposure to the patient and physician.

For more information: www.stereotaxis.com 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init